No Data
No Data
Institutional Owners May Take Dramatic Actions as Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Recent 17% Drop Adds to One-year Losses
Key Insights Significantly high institutional ownership implies Tenaya Therapeutics' stock price is sensitive to their trading actions 52% of the business is held by the top 9 shareholders Analys
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
Express News | Tenaya Therapeutics Inc : William Blair Initiates Coverage With Outperform Rating
William Blair Initiates Tenaya Therapeutics(TNYA.US) With Buy Rating
William Blair analyst Sami Corwin initiates coverage on $Tenaya Therapeutics(TNYA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.9% and a total average return
William Blair Starts Tenaya Therapeutics With Outperform Rating
Tenaya Therapeutics (TNYA) has an average rating of buy and price targets ranging from $7 to $40, according to analysts polled by Capital IQ.
We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate